3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Breast
1
Conditions
Breast Neoplasms
6
Carcinoma, Non-Small-Cell Lung
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Lung Neoplasms
3
Esophageal Neoplasms
3
Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Non-Small Cell Lung Cancer Metastatic
1
Neoplasm Metastasis
1
Meningeal Neoplasms
1
Melanoma
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Endometrial Neoplasms
1
Brain Neoplasms
1
Interventions
Radiosurgery
28
Magnetic Resonance Spectroscopy
15
Temozolomide
14
pembrolizumab
13
Bevacizumab
11
Nivolumab
10
Ipilimumab
8
Memantine
7
Specimen Handling
6
Radiotherapy
6
Mental Status and Dementia Tests
6
abemaciclib
5
Blood Specimen Collection
5
Radiation
4
trastuzumab deruxtecan
3
entrectinib
3
Surveys and Questionnaires
3
Surgical Procedures, Operative
3
Sodium Chloride
3
Saline Solution
3
Receptors, Interleukin-8B
3
Proton Therapy
3
Biopsy
3
trametinib
2
pertuzumab
2
osimertinib
2
lenvatinib
2
fluciclovine F-18
2
contrast agent BR1
2
atezolizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Brain Neoplasms
×
patritumab deruxtecan
×
90 days
×
Clear all
NCT05865990
2026-05-04
TUXEDO-3
MedSIR
Phase 2
Completed
63 enrolled